Analysis of Application of Nivolumab in 179 Patients in Day Chemotherapy Center

QIU Jiuwang; LU Cuiting; ZENG Xiaohua; CHEN Zhuojia; LIU Tao

doi:10.14009/j.issn.1672-2124.2020.05.023

您当前的位置：

首页 >

文章列表页 >

Analysis of Application of Nivolumab in 179 Patients in Day Chemotherapy Center

更新时间：2022-10-08

- Analysis of Application of Nivolumab in 179 Patients in Day Chemotherapy Center
- Vol. 20, Issue 5, Pages: 599-602(2020)
- 作者机构：
  
  中山大学肿瘤防治中心药学部华南肿瘤学国家重点实验室肿瘤医学协同创新中心
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2020.05.023
  CLC： R979.1
- Published：2020，
扫描看全文
[1]丘九望,卢翠婷,曾晓华,陈卓佳,刘韬.179例日间化疗中心患者纳武利尤单抗应用分析[J].中国医院用药评价与分析,2020,20(05):599-602.

QIU Jiuwang, LU Cuiting, ZENG Xiaohua, et al. Analysis of Application of Nivolumab in 179 Patients in Day Chemotherapy Center. [J]. 20(5):599-602(2020)
[1]丘九望,卢翠婷,曾晓华,陈卓佳,刘韬.179例日间化疗中心患者纳武利尤单抗应用分析[J].中国医院用药评价与分析,2020,20(05):599-602. DOI： 10.14009/j.issn.1672-2124.2020.05.023.

QIU Jiuwang, LU Cuiting, ZENG Xiaohua, et al. Analysis of Application of Nivolumab in 179 Patients in Day Chemotherapy Center. [J]. 20(5):599-602(2020) DOI： 10.14009/j.issn.1672-2124.2020.05.023.

摘要

目的:了解国内新上市的程序性死亡蛋白1（programmed death-1

PD-1）抑制剂纳武利尤单抗的临床应用现状与不良反应。方法:通过医院信息系统

检索2018年7月至2019年6月中山大学肿瘤防治中心日间化疗中心纳武利尤单抗的使用数据

并查阅病案及相关检验数据

分析患者基本信息、用药医嘱、联合治疗方案及不良反应等情况。结果:共179例患者使用纳武利尤单抗480例次

男性患者居多（109例

占60. 89%）;年龄集中在40～<70岁（133例

占74. 30%）;所患疾病主要为肺癌（58例

占32. 40%）、肝癌（40例

占22. 35%）、宫颈癌（16例

占8. 94%）和卵巢癌（15例

占8. 38%）。共收集到不良反应203例次（占总用药例次数的42. 29%）

主要体现为骨髓毒性、甲状腺功能异常及肝损伤;其中

血红蛋白减少、白细胞减少、中性粒细胞减少、血小板减少、促甲状腺激素水平升高和丙氨酸氨基转移酶水平升高的发生率较高; 3至4级不良反应共21例次（占总用药例次数的4. 38%）

主要涉及血红蛋白减少。结论:纳武利尤单抗在肿瘤治疗领域取得了突破性进展

但是仍处于免疫治疗的初期

临床存在不少超药品说明书用法

需探讨最佳的联合治疗方法并控制相关不良反应。

Abstract

OBJECTIVE: To investigate the clinical application status and adverse drug reactions of nivolumab

a newly marketed programmed death-1（PD-1） inhibitor in China. METHODS: Hospital information system was used to retrieve the data of application of navulliumab in the day chemotherapy center of Sun Yat-Sen University Cancer Center from Jul. 2018 to Jun. 2019

and the medical records and relevant test data were consulted to analyze the patients’ basic information

medication orders

combined treatment regimens and adverse drug reactions. RESULTS: A total of 179 patients were treated with nivolumab for 480 case-times

most of the patients were male（109 patients

60. 89%）;the age was ranged from 40 to < 70 years（133 cases

74. 30%）. The main diseases were respectively lung cancer（58 cases

32. 40%）

liver cancer（40 cases

22. 35%）

cervical cancer（16 cases

8. 94%） and ovarian cancer（15 cases

8. 38%）. A total of 203 case-times of adverse drug reactions（42. 29% of the total number of case-times）were collected

mainly manifested as bone marrow toxicity

thyroid dysfunction and liver injury. The incidence of hemoglobin reduction

leukopenia

neutropenia

thrombocytopenia

elevated thyrotropin levels and elevated alanine aminotransferase levels were higher. There were 21 case-times of grade 3 to 4 adverse drug reactions（4. 38% of the total number of case-times）

mainly for hemoglobin reduction. CONCLUSIONS: Nivolumab has made a breakthrough in the field of tumor treatment

yet it is still in the early stage of immunotherapy. There are many instructions for the off-label drug use in clinical practice

is necessary to explore the best combined treatment method and control the related adverse drug reactions.

关键词

PD-1抑制剂纳武利尤单抗超药品说明书应用现状不良反应

Keywords

Programmed death-1 inhibitorsNivolumabOff-label useApplication statusAdverse drug reactions

references

查看原文

Views

206

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical Efficacy and Safety of Osimertinib in the Treatment of EGFR Gene Mutation-Positive NSCLC Patients in the Real World

Self-Made Wenyang Tongluo Decoction in the Treatment of Diabetic Peripheral Neuropathy of Yang-Deficiency and Blood-Stasis SyndromeΔ

Literature Review on Adverse Drug Reactions of Liver Injury Induced by Radix Polygoni Multiflori Decoction Pieces and Its Preparations

Rationality and Safety Evaluation of Clinical Application of Nivolumab Injection

Efficacy of Modified Prescription of Kidney-Tonifying and Blood-Invigorate in the Treatment of Knee Osteoarthritis Complicated with Osteoporosis and Its Effect on Serum Toll-like Receptor/Nuclear Factor-κB Signaling Pathway

Related Author

CAO Wei

MIN Qiuxia

DONG Lanlan

TU Wenlian

XU Junfei

ZHANG Qiujin

ZHAO Jun

XU Chunmei

Related Institution

Dept.of Pharmacy, the First People’s Hospital of Yunnan/Kunhua Hospital Affiliated to Kunming University of Science and Technology

College of Pharmacy, Dali University

Dept.of Endocrinology,Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Dept.of Traditional Chinese Medicine, Beijing Friendship Hospital, Capital Medical University

Dept. of Pharmacy, Medical Supplies Center of Chinese PLA General Hospital

⁰